title: (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins.
abstract: Insulin therapy remains the standard of care for achieving and maintaining adequate glycemic control, especially in hospitalized patients with critical and noncritical illnesses. Insulin therapy is more effective against elevated fasting glycaemia but less in the reduction of postprandial hyperglycaemia. It is associated with a high incidence of hypoglycemia and weight gain. Contrary, GLP-1 mimetic therapy improves postprandial glycaemia without the hypoglycaemia and weight gain associated with aggressive insulin therapy. Moreover, it has the potential to reduce cardiovascular related morbidity. However, its increased immunogenicity and severe gastrointestinal adverse effects present a huge burden on patients. Thus, a right combination of basal insulin which has lowering effect on fasting plasma glucose and GLP-1 mimetic with its lowering effect on postprandial plasma glucose with minimal gastrointestinal adverse effects, seems the right therapy choice from a clinical point of view for some diabetic patients. In this article, we discuss the pros and cons of the use of insulin analogues and GLP-1 mimetics that are associated with the treatment of type 2 diabetes.
authors.affiliation: Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia. Electronic address: aljosa.bavec@mf.uni-lj.si.
authors.forename: Aljoša
authors.initials: A
authors.lastname: Bavec
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use*; D061385:Insulins / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D061385:Insulins; D010455:Peptides; D052216:Glucagon-Like Peptide 1
keywords: Diabetes; Glucagon like peptide-1 mimetics; Incretins; Insulin analogues; Peptide drugs